RxDoctor Payments Data

Zane Gates, MD

Internal Medicine · Altoona, PANPI 1649247040

Payments from drug & device makers

$4,478in general payments, 2019–2025

Across 318 payments — averaging $14.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$821
  • GSK$762
  • Novo Nordisk$640
  • Lilly USA, LLC$358
  • Johnson & Johnson$254
  • Pfizer$243
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$4,472100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,478 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$6,160
Medicare patients
29
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$39,235
JardianceEmpagliflozin43$35,221
EliquisApixaban48$33,668
OzempicSemaglutide32$31,376
ArexvyRsvpref3 Antigen/As01e/Pf69$20,868
ShingrixVaricella-Zoster Ge/As01b/Pf86$17,731
TrulicityDulaglutide15$14,884
OxycontinOxycodone Hcl13$13,068
TradjentaLinagliptin14$13,012
Breo ElliptaFluticasone/Vilanterol18$7,641
FarxigaDapagliflozin Propanediol11$6,925
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$5,201
Incruse ElliptaUmeclidinium Bromide11$4,751
AbrysvoRsv Vacc, Pref A And Pref B/Pf13$3,802
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$3,573

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Arexvy, Shingrix, Breo Ellipta, Incruse Ellipta$762$90,227232 claims
Boehringer IngelheimJardiance, Tradjenta$98$48,23257 claims
PfizerEliquis, Abrysvo$243$37,47061 claims
Novo NordiskOzempic$640$31,37632 claims
Lilly USA, LLCTrulicity$358$14,88415 claims
AstraZenecaFarxiga$85$6,92511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Altoona

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →